Clinical Effect of Rebamipide on Chronic Gastritis
Phase 4
Completed
- Conditions
- Gastritis
- Interventions
- Behavioral: optimization of life style
- Registration Number
- NCT02393430
- Lead Sponsor
- BangMao Wang
- Brief Summary
To investigate the clinical effect of rebamipide in chronic gastritis patients. Patients with chronic gastritis were randomly divided into the experimental group and the control group. The experimental group were treated with rebamipide 0.1g tid and optimization of life style, and the control group were only optimized their life style for 26 weeks. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by modified Lanza score (MLS) and the histology by the updated Sydney system before and after treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
- With the symptoms as follow: epigastric pain, abdominal discomfort, abdominal distention, poor appetite, nausea, vomiting and so on
- diagnosed as chronic gastritis with endoscopic and pathological methods
- agree to join in this clinical trail
Exclusion Criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description experimental optimization of life style The experimental group were treated with rebamipide 0.1g tid and optimization of life style. control optimization of life style The control group were only optimized their life style. experimental Rebamipide The experimental group were treated with rebamipide 0.1g tid and optimization of life style.
- Primary Outcome Measures
Name Time Method modified Lanza score 26 weeks visual Analog scale 26 weeks to describe the inflamamtory of gastric mucosa pathologically
- Secondary Outcome Measures
Name Time Method